Abstract
Purpose
To evaluate the effect of preservative-free (PF) tafluprost on diurnal variation of intraocular pressure (IOP) and ocular perfusion pressure (OPP), measured by use of home IOP and blood-pressure (BP) monitoring devices, for primary open angle glaucoma (POAG) patients.
Methods
Twenty-two eyes from 22 patients with POAG were studied. Initially, IOP was measured at the hospital by Goldmann applanation tonometry (GAT) and Icare-ONE rebound tonometry. Each patient was then instructed how to use the Icare-ONE and BP home monitoring devices. IOP and BP were measured at home by the patients, every 4 h, before and 2 weeks after once daily treatment with PF tafluprost (0.0015 %) ophthalmic solution.
Results
Intraclass correlations between different IOP measurements were greater than 0.8. PF tafluprost reduced mean diurnal IOP significantly for patients with POAG, from 15.7 ± 1.2 mmHg at baseline to 12.5 ± 0.6 mmHg 2 weeks after treatment (p < 0.001). It increased mean diurnal OPP from 48.5 ± 7.3 mmHg at baseline to 51.3 ± 7.0 mmHg post-treatment (p < 0.017).
Conclusions
Icare-ONE enables glaucoma patients to measure their own diurnal IOP fluctuations. Patient-measured Icare-ONE IOP readings showed that PF tafluprost effectively reduced diurnal IOP in eyes with POAG.
Similar content being viewed by others
References
Leske MC. Open-angle glaucoma—an epidemiologic overview. Ophthalmic Epidemiol. 2007;14:166–72.
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79.
The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–40.
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.
The American Academy of Ophthalmology Panel. Preffered practice pattern guidelines: primary open-angle glaucoma. The American Academy of Ophthalmology. 2010. http://one.aao.org/preferred-practice-pattern/primary-openangle-glaucoma-ppp--october-2010. Accessed 21 Nov 2014.
Mills RP, Janz NK, Wren PA, Guire KE. Correlation of visual field with quality-of-life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS). J Glaucoma. 2001;10:192–8.
Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma. 2003;12:232–6.
Kontiola A, Puska P. Measuring intraocular pressure with the pulsair 3000 and rebound tonometers in elderly patients without an anesthetic. Graefes Arch Clin Exp Ophthalmol. 2004;242:3–7.
Fernandes P, Diaz-Rey JA, Queiros A, Gonzalez-Meijome JM, Jorge J. Comparison of the ICare rebound tonometer with the Goldmann tonometer in a normal population. Ophthalmic Physiol Opt. 2005;25:436–40.
Martinez-de-la-Casa JM, Garcia-Feijoo J, Castillo A, Garcia-Sanchez J. Reproducibility and clinical evaluation of rebound tonometry. Invest Ophthalmol Vis Sci. 2005;46:4578–80.
Abraham LM, Epasinghe NC, Selva D, Casson R. Comparison of the ICare rebound tonometer with the Goldmann applanation tonometer by experienced and inexperienced tonometrists. Eye. 2008;22:503–6.
Asrani S, Chatterjee A, Wallace DK, Santiago-Turla C, Stinnett S. Evaluation of the ICare rebound tonometer as a home intraocular pressure monitoring device. J Glaucoma. 2011;20:74–9.
Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, et al. Phamacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767–76.
Uusitalo H, Chen E, Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M, et al. Switching from a preserved to a preservative-free prostaglandin preperation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329–36.
Kuwayama Y, Nomura A. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther. 2014;31:461–71.
Nakano T, Yoshikawa K, Kimura T, Suzumura H, Nanno M, Noro T. Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less. Jpn J Ophthalmol. 2011;55:605–13.
Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M. A randomized crossover study comparing tafluprost 0.0015% with travoprost 0.004% in patients with normal-tension glaucoma (corrected). Clin Ophthalmol. 2012;6:1579–84.
van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs-A meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177–85.
Traverso CE, Ropo A, Papadia M, Uusitalo H. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Phamacol Ther. 2010;26:97–104.
Sakata R, Shirato S, Miyata K, Aihara M. Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. Jpn J Ophthalmol. 2014;58:212–7.
Chabi A, Varma R, Tsai JC, Lupinacci R, Pigeon J, Baranak C, et al. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2012;153:1187–96.
Konstas AG, Quaranta L, Katsanos A, Riva I, Tsai JC, Giannopoulos T, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2013;97:1510–5.
Anderson DR, Patella VM. Automated static perimetry. 2nd ed. St. Louis: Mosby; 1999.
Drance SM, Crichton A, Mills RP. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. Am J Ophthalmol. 1998;125:585–92.
Li J, Herndon LW, Asrani SG, Stinnett S, Allingham RR. Clinical comparison of the proview eye pressure monitor with the Goldmann applanation tonometer and the tonopen. Arch Ophthalmol. 2004;122:1117–21.
Mansouri K, Shaarawy T. Continuous intraocular pressure monitoring with a wireless ocular telemetry sensor: initial clinical experience in patients with open angle glaucoma. Br J Ophthalmol. 2011;95:627–9.
Sahin A, Basmak H, Niyaz L, Yildirim N. Reproducibility and tolerability of the ICare rebound tonometer in school children. J Glaucoma. 2007;16:185–8.
Moreno-Montanes J, Martinez-de-la-Casa JM, Sabater AL, Morales L, Saenz C, Garcia-Feijoo J. Clinical evaluation of the new rebound tonometers Icare PRO and Icare ONE compared with the Goldmann tonometer. J Glaucoma. 2014. doi:10.1097/ijg.0000000000000058.
Rosentreter A, Jablonski KS, Mellein AC, Gaki S, Hueber A, Dietlein TS. A new rebound tonometer for home monitoring of intraocular pressure. Graefes Arch Clin Exp Ophthalmol. 2011;249:1713–9.
Halkiadakis I, Stratos A, Stergiopoulos G, Patsea E, Skouriotis S, Mitropoulos P, et al. Evaluation of the Icare-ONE rebound tonometer as a self-measuring intraocular pressure device in normal subjects. Graefes Arch Clin Exp Ophthalmol. 2012;250:1207–11.
Hommer A, Mohammed RO, Burchert M, Kimmich F. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin. 2010;26:1905–13.
Rossi GC, Pasinetti GM, Raimondi M, Ricciardelli G, Scudeller L, Blini M, et al. Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naive ocular hypertension or glaucoma patients. Expert Opi Drug Saf. 2012;11:519–25.
Hwang YH. Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma. Clin Ophthalmol. 2014;8:71–2.
Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–42.
Tsukahara S, Sasaki T. Postural change of IOP in normal persons and in patients with primary wide open-angle glaucoma and low-tension glaucoma. Br J Ophthalmol. 1984;68:389–92.
Liu JH, Kripke DF, Twa MD, Hoffman RE, Mansberger SL, Rex KM, et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci. 1999;40:2912–7.
Sakamoto M, Kanamori A, Fujihara M, Yamada Y, Nakamura M, Negi A. Assessment of IcareONE rebound tonometer for self-measuring intraocular pressure. Acta Ophthalmol. 2014;92:243–8.
Witte V, Glass A, Beck R, Guthoff R. Evaluation of the self-tonometer Icare ONE in comparison to Goldmann applanation tonometry. Ophthalmologe. 2012;109:1008–13.
Lee JY, Yoo C, Jung JH, Hwang YH, Kim YY. The effect of lateral decubitus position on intraocular pressure in healthy young subjects. Acta Ophthalmol. 2012;90:68–72.
Lee JY, Yoo C, Kim YY. The effect of lateral decubitus position on intraocular pressure in patients with untreated open-angle glaucoma. Am J Ophthalmol. 2013;155:329–35.
Lee TE, Yoo C, Kim YY. Effects of different sleeping postures on intraocular pressure and ocular perfusion pressure in healthy young subjects. Ophthalmology. 2013;120:1565–70.
Kim KN, Jeoung JW, Park KH, Lee DS, Kim DM. Effect of lateral decubitus position on intraocular pressure in glaucoma patients with asymmetric visual field loss. Ophthalmology. 2013;120:731–5.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
S. Y. Cho, None; Y. Y. Kim, None; C. Yoo, None; T. -E. Lee, None.
About this article
Cite this article
Cho, S.Y., Kim, Y.Y., Yoo, C. et al. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring. Jpn J Ophthalmol 60, 27–34 (2016). https://doi.org/10.1007/s10384-015-0413-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-015-0413-1